NA Psychedelic Drugs Market - Industry Trends and Forecast to 2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	173 Pages	Data Bridge Market Research	May, 2022	DAABD17330403

Best Price Guarantee
Price	from $3,500
Length	173 Pages
Publisher	Data Bridge Market Research
Published Date	May, 2022
SKU	DAABD17330403

NA Psychedelic Drugs Market - Industry Trends and Forecast to 2029

North America psychedelic drugs market is projected to register a substantial CAGR of 13.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:
North America Global Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

Country (U.S., Canada, Mexico and Rest of North America) Industry Trends and Forecast to 2029

Some of the major factors affecting the growth of North America psychedelic drugs market are:
• Due to increasing prevalence of depression and mental disorder
• Growing Acceptance Of Psychedelic Drugs For Treating Depression

Market Players

The key market players for North America psychedelic drugs market are listed below:
• Jazz Pharmaceuticals, Inc.
• Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
• Hikma Pharmaceuticals PLC
• COMPASS
• Pfizer Inc.
• Avadel
• Cybin Corp.
• Entheon Biomedical Corp
• PharmaTher Holdings Ltd.
• NRx Pharmaceuticals, Inc.
• usonainstitute.org

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of North America Psychedelic Drugs Market; 1.4 Limitations; 1.5 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Currency And Pricing; 2.5 Dbmr Tripod Data Validation Model; 2.6 Multivariate Modelling; 2.7 Type Lifeline Curve; 2.8 Primary Interviews With Key Opinion Leaders; 2.9 Dbmr Market Position Grid; 2.10 Market End User Coverage Grid; 2.11 Vendor Share Analysis; 2.12 Secondary Sources; 2.13 Assumptions
3 Executive Summary
4 Premium Insight: 4.1 Pipeline Analysis; 4.2 Pestel Analysis; 4.3 Porter's Five Forces Model
5 Regulatory Framework: North America Psychedelic Drugs Market: 5.1 Regulatory Scenario In The U.S.; 5.2 Regulatory Scenario In The U.K.; 5.3 Regulatory Scenario In India; 5.4 Regulatory Scenario In Uae; 5.5 Regulatory Scenario In Africa; 5.6 Regulatory Scenario In Brazil
6 Market Overview: 6.1 Drivers; 6.1.1 Growing Acceptance Of Psychedelic Drugs To Treat Depression; 6.1.2 Increasing Prevalence Of Depression And Mental Disorders; 6.1.3 Rising Awareness Toward Mental Health; 6.1.4 Ongoing Clinical Trials; 6.1.5 Rise In Product Approvals; 6.2 Restraints; 6.2.1 Stringent Regulations For Psychedelic Drugs; 6.2.2 High Cost Of Psychedelic Drugs; 6.2.3 Patent Expiry Of Psychedelic Drugs; 6.3 Opportunities; 6.3.1 Increasing R&D Activities In Psychedelic Drugs; 6.3.2 Breakthrough Therapy Designation By Regulatory Authority; 6.3.3 Upcoming Rehabilitation Centers; 6.3.4 Availability Of Certified Healthcare Professionals; 6.4 Challenges; 6.4.1 Side Effects Associated With Psychedelic Drugs; 6.4.2 Rise In Illegal Alternatives; 6.4.3 Availability Of Other Treatment Options
7 Covid-19 Impact On The North America Psychedelic Drugs Market: 7.1 Impact On Price; 7.2 Impact On Demand; 7.3 Impact On Supply Chain; 7.4 Strategic Decisions For Manufacturers; 7.5 Conclusion
8 North America Psychedelic Drugs Market, By Type: 8.1 Overview; 8.2 Empathogens; 8.3 Dissociatives; 8.4 Others
9 North America Psychedelic Drugs Market, By Source: 9.1 Overview; 9.2 Synthetic; 9.3 Natural
10 North America Psychedelic Drugs Market, By Drugs: 10.1 Overview; 10.2 Gamma-hydroxybutyric Acid; 10.3 Ketamine; 10.4 Psilocybin; 10.5 Others
11 North America Psychedelic Drugs Market, By Application: 11.1 Overview; 11.2 Narcolepsy; 11.3 Treatment Resistant Depression; 11.4 Major Depressive Disorder; 11.5 Opiate Addiction; 11.6 Post-traumatic Stress Disorder; 11.7 Others
12 North America Psychedelic Drugs Market, By Route Of Administration: 12.1 Overview; 12.2 Oral; 12.3 Inhalation; 12.4 Injectable
13 North America Psychedelic Drugs Market, By End User: 13.1 Overview; 13.2 Hospitals; 13.3 Specialty Clinics; 13.4 Homecare; 13.5 Others
14 North America Psychedelic Drugs Market, By Distribution Channel: 14.1 Overview; 14.2 Hospitals Pharmacy; 14.3 Retail Pharmacy; 14.4 Online Pharmacy
15 North America Psychedelic Drugs Market, By Region: 15.1 North America; 15.1.1 U.S.; 15.1.2 Canada; 15.1.3 Mexico
16 North America Psychedelic Drugs Market: Company Landscape: 16.1 Company Share Analysis: North America
17 Swot Analysis
18 Company Profile: 18.1 Jazz Pharmaceuticals, Inc.; 18.1.1 Company Snapshot; 18.1.2 Revenue Analysis; 18.1.3 Company Share Analysis; 18.1.4 Product Portfolio; 18.1.5 Recent Developments; 18.2 Pfizer Inc.; 18.2.1 Company Snapshot; 18.2.2 Revenue Analysis; 18.2.3 Company Share Analysis; 18.2.4 Product Portfolio; 18.2.5 Recent Developments; 18.3 F. Hoffmann- La Roche Ltd; 18.3.1 Company Snapshot; 18.3.2 Revenue Analysis; 18.3.3 Company Share Analysis; 18.3.4 Product Portfolio; 18.3.5 Recent Development; 18.4 Janssen North America Services, Llc (A Subsidiary Of Johnson & Johnson Services, Inc.); 18.4.1 Company Snapshot; 18.4.2 Company Share Analysis; 18.4.3 Product Portfolio; 18.4.4 Recent Development; 18.5 Avadel; 18.5.1 Company Snapshot; 18.5.2 Product Portfolio; 18.5.3 Recent Development; 18.6 Celon Pharma Sa; 18.6.1 Company Snapshot; 18.6.2 Product Portfolio; 18.6.3 Recent Development; 18.7 Compass; 18.7.1 Company Snapshot; 18.7.2 Product Portfolio; 18.7.3 Recent Developments; 18.8 Cybin Corp.; 18.8.1 Company Snapshot; 18.8.2 Product Portfolio; 18.8.3 Recent Developments; 18.9 Entheon Biomedical Corp; 18.9.1 Company Snapshot; 18.9.2 Product Portfolio; 18.9.3 Recent Development; 18.10 Gh Research; 18.10.1 Company Snapshot; 18.10.2 Product Portfolio; 18.10.3 Recent Development; 18.11 Hikma Pharmaceuticals Plc; 18.11.1 Company Snapshot; 18.11.2 Revenue Analysis; 18.11.3 Product Portfolio; 18.11.4 Recent Developments; 18.12 Nrx Pharmaceuticals, Inc.; 18.12.1 Company Snapshot; 18.12.2 Product Portfolio; 18.12.3 Recent Development; 18.13 Pharmather Holdings Ltd.; 18.13.1 Company Snapshot; 18.13.2 Product Portfolio; 18.13.3 Recent Development; 18.14 Verrian; 18.14.1 Company Snapshot; 18.14.2 Product Portfolio; 18.14.3 Recent Development; 18.15 Usonainstitute.Org; 18.15.1 Company Snapshot; 18.15.2 Product Portfolio; 18.15.3 Recent Development
19 Questionnaire
20 Related Reports
List Of Tables: Table 1 North America Psychedelic Drugs Market, Pipeline Analysis; Table 2 Psychedelics Research Studies, In Europe; Table 3 Mental Illness In The U.S. Adults, In 2020; Table 4 Mental Disorders, In The U.S. Adults, In 2020; Table 5 Drug Development Pathway For Fda Approval Of New Medications; Table 6 The 1971 Un Convention On Psychotropic Substances; Table 7 Magic Mushrooms Prices For Researchers, In The U.S.; Table 8 Cost Of Psychedelic Drugs; Table 9 Psychedelic Drugs R&D Activities; Table 10 North America Psychedelic Drugs Market, By Type, 2020-2029 (Usd Million); Table 11 North America Empathogens In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 12 North America Dissociatives In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 13 North America Others In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 14 North America Psychedelic Drugs Market, By Source, 2020-2029 (Usd Million); Table 15 North America Synthetic In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 16 North America Natural In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 17 North America Psychedelic Drugs Market, By Drugs, 2020-2029 (Usd Million); Table 18 North America Gamma-hydroxybutyric Acid In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 19 North America Ketamine In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 20 North America Psilocybin In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 21 North America Others In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 22 North America Psychedelic Drugs Market, By Application, 2020-2029 (Usd Million); Table 23 North America Narcolepsy In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 24 North America Treatment Resistant Depression In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 25 North America Major Depressive Disorder In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 26 North America Opiate Addiction In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 27 North America Post-traumatic Stress Disorder In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 28 North America Others In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 29 North America Psychedelic Drugs Market, By Route Of Administration, 2020-2029 (Usd Million); Table 30 North America Oral In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 31 North America Inhalation In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 32 North America Injectable In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 33 North America Psychedelic Drugs Market, By End User, 2020-2029 (Usd Million); Table 34 North America Hospitals In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 35 North America Specialty Clinics In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 36 North America Homecare In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 37 North America Others In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 38 North America Psychedelic Drugs Market, By Distribution Channel, 2020-2029 (Usd Million); Table 39 North America Hospitals Pharmacy In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 40 North America Retail Pharmacy In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 41 North America Online Pharmacy In Psychedelic Drugs Market, By Region, 2020-2029 (Usd Million); Table 42 North America Psychedelic Drugs Market, By Country, 2020-2029 (Usd Million); Table 43 North America Psychedelic Drugs Market, By Type, 2020-2029 (Usd Million); Table 44 North America Psychedelic Drugs Market, By Source, 2020-2029 (Usd Million); Table 45 North America Psychedelic Drugs Market, By Drugs, 2020-2029 (Usd Million); Table 46 North America Psychedelic Drugs Market, By Application, 2020-2029 (Usd Million); Table 47 North America Psychedelic Drugs Market, By Route Of Administration, 2020-2029 (Usd Million); Table 48 North America Psychedelic Drugs Market, By End User, 2020-2029 (Usd Million); Table 49 North America Psychedelic Drugs Market, By Distribution Channel, 2020-2029 (Usd Million); Table 50 U.S. Psychedelic Drugs Market, By Type, 2020-2029 (Usd Million); Table 51 U.S. Psychedelic Drugs Market, By Source, 2020-2029 (Usd Million); Table 52 U.S. Psychedelic Drugs Market, By Drugs, 2020-2029 (Usd Million); Table 53 U.S. Psychedelic Drugs Market, By Application, 2020-2029 (Usd Million); Table 54 U.S. Psychedelic Drugs Market, By Route Of Administration, 2020-2029 (Usd Million); Table 55 U.S. Psychedelic Drugs Market, By End User, 2020-2029 (Usd Million); Table 56 U.S. Psychedelic Drugs Market, By Distribution Channel, 2020-2029 (Usd Million); Table 57 Canada Psychedelic Drugs Market, By Type, 2020-2029 (Usd Million); Table 58 Canada Psychedelic Drugs Market, By Source, 2020-2029 (Usd Million); Table 59 Canada Psychedelic Drugs Market, By Drugs, 2020-2029 (Usd Million); Table 60 Canada Psychedelic Drugs Market, By Application, 2020-2029 (Usd Million); Table 61 Canada Psychedelic Drugs Market, By Route Of Administration, 2020-2029 (Usd Million); Table 62 Canada Psychedelic Drugs Market, By End User, 2020-2029 (Usd Million); Table 63 Canada Psychedelic Drugs Market, By Distribution Channel, 2020-2029 (Usd Million); Table 64 Mexico Psychedelic Drugs Market, By Type, 2020-2029 (Usd Million); Table 65 Mexico Psychedelic Drugs Market, By Source, 2020-2029 (Usd Million); Table 66 Mexico Psychedelic Drugs Market, By Drugs, 2020-2029 (Usd Million); Table 67 Mexico Psychedelic Drugs Market, By Application, 2020-2029 (Usd Million); Table 68 Mexico Psychedelic Drugs Market, By Route Of Administration, 2020-2029 (Usd Million); Table 69 Mexico Psychedelic Drugs Market, By End User, 2020-2029 (Usd Million); Table 70 Mexico Psychedelic Drugs Market, By Distribution Channel, 2020-2029 (Usd Million)
List Of Figures: Figure 1 North America Psychedelic Drugs Market: Segmentation; Figure 2 North America Psychedelic Drugs Market : Data Triangulation; Figure 3 North America Psychedelic Drugs Market: Droc Analysis; Figure 4 North America Psychedelic Drugs Market: North America Vs Regional Market Analysis; Figure 5 North America Psychedelic Drugs Market: Company Research Analysis; Figure 6 North America Psychedelic Drugs Market: Multivariate Modelling; Figure 7 North America Psychedelic Drugs Market: Interview Demographics; Figure 8 North America Psychedelic Drugs Market: Dbmr Market Position Grid; Figure 9 North America Psychedelic Drugs Market: End User Coverage Grid; Figure 10 North America Psychedelic Drugs Market: Vendor Share Analysis; Figure 11 North America Psychedelic Drugs Market: Segmentation; Figure 12 North America Is Expected To Dominate The North America Psychedelic Drugs Market Growing With The Highest Cagr In The Forecast Period Of 2022 To 2029; Figure 13 Rising Awareness Towards Merantal Health Driving The North America Psychedelic Drugs Market In The Forecast Period Of 2022 To 2029; Figure 14 Empathogens Segment Is Expected To Account For The Largest Share Of The North America Psychedelic Drugs Market In 2022 & 2029; Figure 15 Drivers, Restraints, Opportunities, And Challenges Of The North America Psychedelic Drugs Market; Figure 16 Mental Illness Among The U.S. Adults, In 2020, (In %), By Demographic Groups; Figure 17 Mental Illness Treatment Rates Among The U.S. Adults, In 2020, (In %), By Demographic Groups; Figure 18 Mental Illness Treatment Rates Among The U.S. Adults, In 2020, (In %), By Gender; Figure 19 North America Psychedelic Drugs Market: By Type, 2021; Figure 20 North America Psychedelic Drugs Market: By Type, 2022-2029 (Usd Million); Figure 21 North America Psychedelic Drugs Market: By Type, Cagr (2022-2029); Figure 22 North America Psychedelic Drugs Market: By Type, Lifeline Curve; Figure 23 North America Psychedelic Drugs Market: By Source, 2021; Figure 24 North America Psychedelic Drugs Market: By Source, 2022-2029 (Usd Million); Figure 25 North America Psychedelic Drugs Market: By Source, Cagr (2022-2029); Figure 26 North America Psychedelic Drugs Market: By Source, Lifeline Curve; Figure 27 North America Psychedelic Drugs Market: By Drugs, 2021; Figure 28 North America Psychedelic Drugs Market: By Drugs, 2022-2029 (Usd Million); Figure 29 North America Psychedelic Drugs Market: By Drugs, Cagr (2022-2029); Figure 30 North America Psychedelic Drugs Market: By Drugs, Lifeline Curve; Figure 31 North America Psychedelic Drugs Market: By Application, 2021; Figure 32 North America Psychedelic Drugs Market: By Application, 2022-2029 (Usd Million); Figure 33 North America Psychedelic Drugs Market: By Application, Cagr (2022-2029); Figure 34 North America Psychedelic Drugs Market: By Application, Lifeline Curve; Figure 35 North America Psychedelic Drugs Market: By Route Of Administration, 2021; Figure 36 North America Psychedelic Drugs Market: By Route Of Administration, 2022-2029 (Usd Million); Figure 37 North America Psychedelic Drugs Market: By Route Of Administration, Cagr (2022-2029); Figure 38 North America Psychedelic Drugs Market: By Route Of Administration, Lifeline Curve; Figure 39 North America Psychedelic Drugs Market: By End User, 2021; Figure 40 North America Psychedelic Drugs Market: By End User, 2022-2029 (Usd Million); Figure 41 North America Psychedelic Drugs Market: By End User, Cagr (2022-2029); Figure 42 North America Psychedelic Drugs Market: By End User, Lifeline Curve; Figure 43 North America Psychedelic Drugs Market: By Distribution Channel, 2021; Figure 44 North America Psychedelic Drugs Market: By Distribution Channel, 2022-2029 (Usd Million); Figure 45 North America Psychedelic Drugs Market: By Distribution Channel, Cagr (2022-2029); Figure 46 North America Psychedelic Drugs Market: By Distribution Channel, Lifeline Curve; Figure 47 North America Psychedelic Drugs Market: Snapshot (2021); Figure 48 North America Psychedelic Drugs Market: By Country (2021); Figure 49 North America Psychedelic Drugs Market: By Country (2022 & 2029); Figure 50 North America Psychedelic Drugs Market: By Country (2021 & 2029); Figure 51 North America Psychedelic Drugs Market: By Type (2022-2029); Figure 52 North America Psychedelic Drugs Market: Company Share 2021 (%)